Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription

Detalhes bibliográficos
Autor(a) principal: Bolani,Bruna
Data de Publicação: 2021
Outros Autores: Oliveira,Gabriela Moraes, Dionísio,Thiago José, Faria,Flavio Augusto Cardoso, Fernandes,Maria Helena Raposo, Santos,Carlos Ferreira, Calvo,Adriana Maria
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Dental Journal
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-64402021000100003
Resumo: Abstract Saliva is widely used for clinical and laboratory analysis. This study proposed to use DNA extracted from saliva for genotyping and pharmacokinetics of piroxicam. A fast and efficient genotyping method was used to determine relevant allelic variants of CYP2C9 (*2 and *3), since genetic factors can influence in non-steroidal anti-inflammatory drugs (NSAIDs) metabolization. DNA Extract All Reagents Kit® was used for DNA extraction and genotyping was performed using TaqMan® GTXpress™ Master Mix, SNP genotyping assays and a Viia7 Real-Time PCR system. Volunteers performed sequential collections of saliva samples before and after taking a single dose of piroxicam (0.25 to 72 h) which were used for pharmacokinetics assays. Piroxicam concentrations were analyzed using LC-MS/MS. Sixty-six percent of volunteers were ancestral homozygous (CYP2C9*1/*1), and 34% showed one or both polymorphisms. Of these 34%, 22 individuals showed CYP2C9*2 polymorphism, 8 CYP2C9*3, and 4 CYP2C9*2/*3. Piroxicam pharmacokinetics were performed in 5 subjects. Areas under the curve (AUC0-t(h*ng/mL)) for CYP2C9*1/*1, *1/*2 and *1/*3 were, respectively, 194.33±70.93, 166 and 303. Maximum concentrations (Cmax(ng/mL)) for these genotypes were respectively 6.46±2.56, 4.3 and 10.2. Saliva sampling was a very effective matrix for both pharmacogenetic and pharmacokinetic tests, ensuring the speed of the procedure and the well-being and agreement of the participants. Once having the knowledge about the slow and fast metabolizers, it is possible to make an adequate prescription in order to avoid the adverse effects of the medication and to guarantee greater analgesic comfort to the patients respectively.
id FUNORP-1_d66f1dbd5fac6843cb8a8a5df79025c4
oai_identifier_str oai:scielo:S0103-64402021000100003
network_acronym_str FUNORP-1
network_name_str Brazilian Dental Journal
repository_id_str
spelling Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug PrescriptiongenotypingDNApharmacokineticNSAIDsalivaAbstract Saliva is widely used for clinical and laboratory analysis. This study proposed to use DNA extracted from saliva for genotyping and pharmacokinetics of piroxicam. A fast and efficient genotyping method was used to determine relevant allelic variants of CYP2C9 (*2 and *3), since genetic factors can influence in non-steroidal anti-inflammatory drugs (NSAIDs) metabolization. DNA Extract All Reagents Kit® was used for DNA extraction and genotyping was performed using TaqMan® GTXpress™ Master Mix, SNP genotyping assays and a Viia7 Real-Time PCR system. Volunteers performed sequential collections of saliva samples before and after taking a single dose of piroxicam (0.25 to 72 h) which were used for pharmacokinetics assays. Piroxicam concentrations were analyzed using LC-MS/MS. Sixty-six percent of volunteers were ancestral homozygous (CYP2C9*1/*1), and 34% showed one or both polymorphisms. Of these 34%, 22 individuals showed CYP2C9*2 polymorphism, 8 CYP2C9*3, and 4 CYP2C9*2/*3. Piroxicam pharmacokinetics were performed in 5 subjects. Areas under the curve (AUC0-t(h*ng/mL)) for CYP2C9*1/*1, *1/*2 and *1/*3 were, respectively, 194.33±70.93, 166 and 303. Maximum concentrations (Cmax(ng/mL)) for these genotypes were respectively 6.46±2.56, 4.3 and 10.2. Saliva sampling was a very effective matrix for both pharmacogenetic and pharmacokinetic tests, ensuring the speed of the procedure and the well-being and agreement of the participants. Once having the knowledge about the slow and fast metabolizers, it is possible to make an adequate prescription in order to avoid the adverse effects of the medication and to guarantee greater analgesic comfort to the patients respectively.Fundação Odontológica de Ribeirão Preto2021-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-64402021000100003Brazilian Dental Journal v.32 n.1 2021reponame:Brazilian Dental Journalinstname:Fundação Odontológica de Ribeirão Preto (FUNORP)instacron:FUNORP10.1590/0103-6440202104059info:eu-repo/semantics/openAccessBolani,BrunaOliveira,Gabriela MoraesDionísio,Thiago JoséFaria,Flavio Augusto CardosoFernandes,Maria Helena RaposoSantos,Carlos FerreiraCalvo,Adriana Mariaeng2021-03-30T00:00:00Zoai:scielo:S0103-64402021000100003Revistahttps://www.scielo.br/j/bdj/https://old.scielo.br/oai/scielo-oai.phpbdj@forp.usp.br||sergio@fosjc.unesp.br1806-47600103-6440opendoar:2021-03-30T00:00Brazilian Dental Journal - Fundação Odontológica de Ribeirão Preto (FUNORP)false
dc.title.none.fl_str_mv Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription
title Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription
spellingShingle Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription
Bolani,Bruna
genotyping
DNA
pharmacokinetic
NSAID
saliva
title_short Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription
title_full Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription
title_fullStr Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription
title_full_unstemmed Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription
title_sort Pharmacogenetic and Pharmacokinetic Assays from Saliva Samples Can Guarantee Personalized Drug Prescription
author Bolani,Bruna
author_facet Bolani,Bruna
Oliveira,Gabriela Moraes
Dionísio,Thiago José
Faria,Flavio Augusto Cardoso
Fernandes,Maria Helena Raposo
Santos,Carlos Ferreira
Calvo,Adriana Maria
author_role author
author2 Oliveira,Gabriela Moraes
Dionísio,Thiago José
Faria,Flavio Augusto Cardoso
Fernandes,Maria Helena Raposo
Santos,Carlos Ferreira
Calvo,Adriana Maria
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Bolani,Bruna
Oliveira,Gabriela Moraes
Dionísio,Thiago José
Faria,Flavio Augusto Cardoso
Fernandes,Maria Helena Raposo
Santos,Carlos Ferreira
Calvo,Adriana Maria
dc.subject.por.fl_str_mv genotyping
DNA
pharmacokinetic
NSAID
saliva
topic genotyping
DNA
pharmacokinetic
NSAID
saliva
description Abstract Saliva is widely used for clinical and laboratory analysis. This study proposed to use DNA extracted from saliva for genotyping and pharmacokinetics of piroxicam. A fast and efficient genotyping method was used to determine relevant allelic variants of CYP2C9 (*2 and *3), since genetic factors can influence in non-steroidal anti-inflammatory drugs (NSAIDs) metabolization. DNA Extract All Reagents Kit® was used for DNA extraction and genotyping was performed using TaqMan® GTXpress™ Master Mix, SNP genotyping assays and a Viia7 Real-Time PCR system. Volunteers performed sequential collections of saliva samples before and after taking a single dose of piroxicam (0.25 to 72 h) which were used for pharmacokinetics assays. Piroxicam concentrations were analyzed using LC-MS/MS. Sixty-six percent of volunteers were ancestral homozygous (CYP2C9*1/*1), and 34% showed one or both polymorphisms. Of these 34%, 22 individuals showed CYP2C9*2 polymorphism, 8 CYP2C9*3, and 4 CYP2C9*2/*3. Piroxicam pharmacokinetics were performed in 5 subjects. Areas under the curve (AUC0-t(h*ng/mL)) for CYP2C9*1/*1, *1/*2 and *1/*3 were, respectively, 194.33±70.93, 166 and 303. Maximum concentrations (Cmax(ng/mL)) for these genotypes were respectively 6.46±2.56, 4.3 and 10.2. Saliva sampling was a very effective matrix for both pharmacogenetic and pharmacokinetic tests, ensuring the speed of the procedure and the well-being and agreement of the participants. Once having the knowledge about the slow and fast metabolizers, it is possible to make an adequate prescription in order to avoid the adverse effects of the medication and to guarantee greater analgesic comfort to the patients respectively.
publishDate 2021
dc.date.none.fl_str_mv 2021-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-64402021000100003
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0103-64402021000100003
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0103-6440202104059
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Fundação Odontológica de Ribeirão Preto
publisher.none.fl_str_mv Fundação Odontológica de Ribeirão Preto
dc.source.none.fl_str_mv Brazilian Dental Journal v.32 n.1 2021
reponame:Brazilian Dental Journal
instname:Fundação Odontológica de Ribeirão Preto (FUNORP)
instacron:FUNORP
instname_str Fundação Odontológica de Ribeirão Preto (FUNORP)
instacron_str FUNORP
institution FUNORP
reponame_str Brazilian Dental Journal
collection Brazilian Dental Journal
repository.name.fl_str_mv Brazilian Dental Journal - Fundação Odontológica de Ribeirão Preto (FUNORP)
repository.mail.fl_str_mv bdj@forp.usp.br||sergio@fosjc.unesp.br
_version_ 1754204096187858944